TIANJIN, CHINA: 6th April, 2021.
HAIMEN, CHINA: 31st March, 2021
Crystec are delighted to have been selected as a finalist for the 2020 CPhI Excellence in Pharma Awards in the category of Innovation in Response to COVID-19.
CrystecPharma are pleased to announce the approval of patent applications for their lead asset, CR002. Applications with China’s National Intellectual Property Administration (CNIPA) and the European Patent Office (EPO) have recently been approved. National filings are ongoing in other key territories.